Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
PHILADELPHIA, Jan. 26, 2016 -- Medgenics, Inc. (NYSE MKT:MDGN), today announced that members of its management team will participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day on Tuesday, February 2, 2016 in New York, NY.
About Medgenics, Inc.
Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. For more information, visit the Company's website at www.medgenics.com.
Contacts: Medgenics, Inc. Brian Piper [email protected]
